Autopsy report · NCT00618696

Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia

“Replaced with another study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 7 months after it had already started.
• Ran for about 2 years 5 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Leukemia; Myelodysplastic Syndromes

Interventions

anti-CD45 monoclonal antibody AHN-12; yttrium Y 90 anti-CD45 monoclonal antibody AHN-12

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• MT2004-30: Tomotherapy for Solid Tumors
  “Replaced by another study” (98% match in meaning)
• Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients
  “replaced by a new study” (94% match in meaning)
• Estimate Serum Oxytocin PD Range in the Periphery
  “Study will be replaced by a revised study protocol” (78% match in meaning)
• Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes
  “study merged with another study” (74% match in meaning)
• Study of Body Composition Methodology in Young Children (InfantPod)
  “This study will not be conducted. A new study is replacing this one.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.